Serum angiostatin and endostatin level in patients with granulomatosis with polyangiitis and immune complex small vessel vasculitis
Data nadesłania: 11-08-2018
Data ostatniej rewizji: 24-08-2018
Data akceptacji: 25-08-2018
Data publikacji online: 31-10-2018
Data publikacji: 31-10-2018
Reumatologia 2018;56(5):285-288
Inflammation has been revealed to be associated with angiogenesis. Granulomatosis with polyangiitis (GPA) and immune complex small vessel vasculitis (ICSVV) are forms of systemic vasculitides of different pathogenesis. GPA is a necrotizing granulomatosis and ICSVV is associated with inflammation of postcapillary venules induced by deposits of immune complexes. The aim of the study was to determine serum levels of angiostatin and endostatin, natural angiogenesis inhibitors, in patients with GPA and ICSVV as well as healthy individuals.

Material and methods:
Two groups of patients with GPA (20 patients) and ICSVV (20 patients) as well as 20 controls were investigated. All patients were investigated before initiation of immunosuppressive therapy or administration of corticosteroids. Angiostatin and endostatin levels were assayed with the ELISA method.

Enhanced serum levels of angiostatin and endostatin were found in patients with GPA but not in those suffering from ICSVV. In patients with GPA increased levels of angiogenesis inhibitors correlated with the disease activity. A correlation between angiostatin and endostatin levels was observed in all groups of investigated individuals.

It is suggested that formation of necrotizing granulation is associated with profound activation of angiogenesis and an increase in serum levels of inhibitors is a phenomenon occurring during blood vessel formation in the granulation tissue. The obtained results confirm involvement of angiogenesis in pathogenesis of at least some forms of vasculitides and suggest the need for continuation of investigations in this field.

Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
Lamprecht P, Kerstein A, Klapa S, et al. Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front Immunol 2018; 9: 680.
Villa-Forte A. European League Against Rheumatism – European Vasculitis Study Group Recommendations for the Management of Vasculitis. Curr Opin Rheumatol 2010; 22: 49-53.
Sznajd J, Mukhtyar C. How to treat ANCA-associated vasculitis: practical messages from 2016 EULAR/ERA-EDTA recommendations. Pol Arch Med Wewn 2016; 126: 781-788.
Masiak A, Zdrojewski Z, Pęksa R, et al. The usefulness of histopathological examination of non-renal biopsies in the diagnosis of granulomatosis with polyangiitis. Reumatologia 2017; 55: 230-236.
Kucharz EJ. Vasculitides. In: Treatment of rheumatic disorders, Zimmermann-Górska I. (ed.). PZWL Wydawnictwo Lekarskie, Warszawa 2018: 204-251 (in Polish).
Claudy A. Pathogenesis of leukocytoclastic vasculitis. Eur J Dermatol 1998; 8: 75-79.
Kolopp-Sarda MN, Miossec P. Cryoglobulins: An update on detection, mechanisms and clinical contribution. Autoimmun Rev 2018; 17: 457-464.
Kotulska A, Kucharz EJ. Angiogenesis in rheumatoid arthritis. Reumatologia 2011; 49: 1-9.
O’Neill L, Rooney P, Molloy D, et al. Regulation of inflammation and angiogenesis in giant cell arteritis by acute-phase serum amyloid A. Arthritis Rheum 2015; 67: 2447-2456.
Kotulska A, Mazurek U, Kotyla P, et al. Angiostatin, a natural inhibitor of angiogenesis. Por Farmaceut 2006; 1: 1-4 (in Polish).
Wahl ML, Kenan DJ, Gonzalez-Gronow M, et al. Angiostatin’s molecular mechanism: aspects of specificity and regulation elucidated. J Cell Biochem 2005; 96: 242-261.
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: on endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
Kucharz EJ, Kotulska A. Pathophysiology of endostatin in non-malignant diseases. Pol Arch Med Wewn 2006; 115: 507-511 (in Polish).
Walia A, Yang JF, Huang YH, et al. Endostatin’s emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta 2015; 1850: 2422-2438.
Leavit RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 1990; 33: 1101-1107.
Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener’s granulomatosis. Arthritis Rheum 2001; 44: 912-920.
Keskin D, Keskin G, Inal A, et al. Serum angiostatin levels in patients with Behçet’s disease: does angiogenesis play a role in the pathogenesis of Behçet’s disease? Acta Clin Belg 2014; 69: 246-216.
Takeshita S, Kawamura Y, Takabayashi H, et al. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exper Immunol 2005; 139: 575-579.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top